ductivity. These characteristics permit a larger volume of tissue to be ablated for a given energy than in other tissues in the body [16] . With RFA, an electrode from a generator causes frictional heating, elevating tissue temperature to 60-100°C. This creates a necrotic zone covering both the tumor and margin of normal parenchyma [17] . However, this thermal energy can be limited by the heat-sink effect of adjacent blood vessels and airways [1] . Several groups have reported that the presence of vessels or bronchi greater than 3 mm in diameter within the ablation zone are predictors of incomplete local treatment [18, 19] . Pathologic analyses of 354 NSCLC cases (adenocarcinoma and squamous cell carcinoma) have revealed that 8 and 6 mm margins, respectively, are needed to cover 95% of microscopic disease extension [20] . Thus to obtain adequate margins, the ablation zone must exceed the tumor size [21] . RFA therefore performs best for lesions smaller than 2 cm, with rates of complete ablation ranging from 78% to 96% with a mean follow-up of 1 year [3, 14, 18, 22, 23] . Lower success rates are seen with tumors 2-3 cm in diameter [3, 18, 22, 23] . More specifically, a ratio of RFA-induced ground-glass opacity (GGO) to tumor area of greater than 4 (bidimensional area on axial images) is correlated with a significantly higher rate of complete ablation than a ratio of less than or equal to 4 [3] .
A variety of image-guided thermal ablation techniques exist for patients with non-small cell lung carcinoma (NSCLC) and oligometastatic disease. Many of these patients are not surgical candidates, so thermal ablation techniques-including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation-have been explored, showing safety, efficacy, and good local disease control while preserving the lung parenchyma [1] [2] [3] [4] [5] [6] [7] [8] . For patients with stage I or II NSCLC, surgical resection provides the best curative option, with 5-year survival rates of 50-75% [9] . However, only one-third of patients may meet the criteria for lobar or sublobar resection [10] . For the remaining patients, ablative therapies have proved useful [3, [11] [12] [13] [14] . Additionally, the lungs are the second most common site of metastatic disease [15] . In selected patients with a limited number of tumors that can be ablated with adequate margins or those who present with residual or recurrent disease after having undergone other treatments, percutaneous thermal ablation plays a role in disease management. Over the past 2 decades, ablation has played an important role in the treatment of both primary and secondary pulmonary malignancies, providing an effective therapy, which can also provide potential cure in select cases.
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simultaneous energy delivery with multiple probes, thus permitting larger ablation zones than RFA. In animal studies, investigators have reported lung ablation zones as large as 54.8 ± 8.5 mm (mean ± SD) [25] . Clinically, Wolf et al. [4] reported MWA results in 50 patients with pulmonary tumors up to 5 cm. The authors reported an overall recurrence rate of 26% and a tumor size of larger than 3 cm being predictive of recurrent disease.
Cryoablation uses compressed argon gas to generate subzero temperatures with iceball formation. When temperatures are less than -40°C, protein denaturation, cell rupture, and ischemia occur [26] . Unlike heatbased ablation, cryoablation does not create GGO intraprocedurally; instead, the ice ball is used to estimate the ablated margin. Hinshaw et al. [27] examined the temperature isotherms and associated ablation zone size seen with cryoablation in an in vivo porcine lung model. They identified the −20°C isotherm as the zone of coagulative necrosis, with a mean ablation zone diameter of 2.4 ± 0.2 cm [27] . Most ablation protocols call for three freezethaw cycles to achieve tissue necrosis [27, 28] .
Irreversible electroporation, which uses electrical pulses to generate high electrical fields (1500 V/cm 2 ), was developed as a nonthermal ablation technique. This technique causes cellular apoptosis by creating cell membrane pores and resultant cell lysis. However, in the multicenter phase II trial of 23 patients with metastatic disease, Ricke et al. [29] reported local progression in 61% of treated patients. They postulated that the high local recurrence was likely because of conductivity differences between the tumor tissue and normal lung parenchyma. Given these results, irreversible electroporation requires refinement before becoming an effective ablation modality for pulmonary malignancies.
Imaging and Response
CT is the preferred image guidance modality for thermal ablation because it provides excellent contrast between the tumor tissue and normal aerated lung. CT provides multiplanar imaging, which facilitates accurate and quick probe placement [30] . In fact, operators who have access to multiplanar imaging have been shown to better distinguish between margin-and lesion-centered probe placement than operators who have access to axial images alone [31] . Cone-beam CT has been used for lung ablation because it facilitates ablation approaches from any angle; however, it lacks real-time imaging capability. This can be an issue in the setting of moving target lesions [32] .
CT is also the modality of choice for follow-up after ablation. After ablation, the targeted lesion is replaced by a central area of increased radiographic density that is surrounded by GGO [11] , which may overestimate the actual pathologic margins of RFA [33] and cryoablation [28] . An ablation margin surrounding the target lesion of less than 4.5 mm or an incomplete margin has been correlated with local tumor progression [34] . GGO margins of less than 3 mm have been associated with tumor progression as well [35] . During the initial postablation period (< 2 months), this dense opacification and surrounding GGO serve as the new "baseline" postablation image [21, 36] . Any increase in the size of this lesion on follow-up should be considered local progression.
The evolution of the imaging appearance of the ablation zone varies depending on the thermal ablation modality. Palussière et al.
[37] described the involution pattern seen after RFA of 350 treated lesions with CT followup up to 12 months. Although they reported five different imaging patterns, they concluded that none of these patterns can be used to exclude local tumor progression. RFA-treated lesions show a relatively slow rate of involution, with a 40% decrease in size at 15 months after treatment [38] . Similar postablation imaging findings have been described after MWA [4] (Fig. 1) . Cryoablated lesions, however, show faster involution on CT follow-up so that local tumor progression can be visualized as early as 6 months after treatment [39] . CT enhancement patterns after both RFA and cryoablation have not shown correlation with local progression [6, 39] . CT is therefore primarily used to examine morphologic changes to the ablation zone. However, detecting local progression at follow-up using CT alone remains difficult. Beland et al. [40] found that in 79 patients with NSCLC treated using RFA, local progression was seen in only 1.5% at 6 months, increasing to 10.1% at 1 year and 28% at 2 years. De Baère et al. [13] retrospectively examined the records and images of 566 patients with meta static disease treated with RFA and reported rates of local tumor progression of 10.4% at 1 year and 18.1% at 4 years.
To overcome the limitations of CT's morphologic assessment of local recurrence, PET/CT follow-up has been explored (Table 1). Yoo et al. [41] examined the role of PET/CT in 30 patients with stage I NSCLC treated with RFA. They reported that imaging 6 months after RFA more accurately reflected outcomes at 1 year than imaging performed immediately after RFA [41] . Suzawa et al. [33] studied the utility of PET/CT in the follow-up of 143 patients treated with RFA. Local tumor progression was seen in 20.4% of tumors with a median follow-up of 24 months, and PET's diagnostic performance exceeded that of CT at all follow-up imaging time points. However, for up to 3 months after ablation, PET/CT Long-term data after MWA for the treatment of NSCLC are limited. Wolf et al. [4] reported outcomes after MWA of NSCLC in 30 patients. With a mean follow-up of 10 months, Wolf et al. found a local recurrence rate of 26%, which was significantly increased in lesions larger than 3 cm on logistic regression analysis. OS rates ranged from 65% at 1 year to 45% at 3 years, which were not associated with tumor size [4] . Lu et al. [54] studied outcomes in 183 patients (138 of whom had primary lung cancer) treated with MWA. The local progression rate was 19.1%, with an increased risk of progression seen in patients with lesions larger than 3 cm and in the setting of emphysema on multivariate analysis [54] . The authors reported a median progression-free survival (PFS) and CSS of 16.5 and 29.0 months. Tumor stage and diameter greater than 3 cm were independent risk factors for CSS on multivariate analysis. A recent retrospective study by Healey et al.
[55] examined outcomes of 108 patients (82 NSCLCs) who underwent MWA with a median follow-up of 14.1 months. The authors found significantly higher rates of technical success with lesions less than 3 cm in diameter. The median time to tumor recurrence was 62 months, with recurrence rates ranging from 22% at 1 year to 44% at 3 years. Significantly lower rates of recurrence were seen with lesions less than 3 cm. The median OS was 27.1 months, with 1-and 3-year OS rates of 78% and 39%.
Although the long-term studies on cryoablation of NSCLC are limited, the initial studies have yielded promising results. found longer median OS in patients treated with RFA and chemotherapy (n = 24) than in those treated with chemotherapy alone (n = 18) (42 vs 29 months, respectively; p < 0.03). Ablation has also been used in patients with a solitary lung after pneumonectomy, a population with few treatment options for new or recurrent disease and limited pulmonary reserve. Hess et al. [12] and Sofocleous et al.
[61] have shown acceptable morbidity and safety of ablation in treating these patients. Sofocleous et al. [61] caution that postablation pneumonitis may be a concern in these patients and may be mitigated with periprocedural steroid administration.
Metastatic Disease
Thermal ablation plays a role in the management of metastatic disease in selected patients with limited disease burden that can be ablated with margins. In general, this group includes patients with up to four lesions per lung and with lesions smaller than 3.5 cm [6, [62] [63] [64] [65] . Given the clinical course of metastatic disease, the therapies should be repeatable and associated with limited effects on pulmonary function [5, 63, 66] . The Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE) trial in 53 patients with metastatic colorectal carcinoma (CRC) reported 1-and 2-year OS rates of 89% and 66% [14] . De Baère et al. [13] reported the largest series of pulmonary metastases (566 patients with 1037 metastases) treated with RFA. The authors reported a Image-Guided Thermal Ablation of Pulmonary Tumors median OS of 62 months and 1-and 5-year OS rates of 92.4% and 51.5% for the entire cohort. On multivariate analysis, the location of the primary tumor, disease-free interval, tumor size greater than 2 cm, and presence of more than three metastases were associated with OS. Several studies have reported similar 1-and 3-year OS rates [67, 68] . Most series evaluating RFA for metastatic disease report local progression rates of 10-30%, especially for lesions larger than 3 cm [14, 18, 63, [69] [70] [71] . Omae et al. [72] reported longterm follow-up in 123 patients with lung oligometastases treated with RFA. The authors found a 5-year OS rate and recurrencefree survival rate of 62% and 25% [72] .
MWA has also been explored for the treatment of pulmonary metastatic disease. Vogl et al. [5] reported outcomes of MWA in 80 patients with metastatic disease. The authors found a rate of local recurrence of 26%, with treatment success significantly related to tumor size less than 3 cm and to peripheral lesions rather than central lesions. The 1-and 2-year survival rates were 91.3% and 75%. In a follow-up study in 57 patients with 91 metastatic lesions [73] , local progression was seen in 33% of patients, with a median time to local progression of 22.6 ± 12.4 months. On regression analysis, the shape of the primary lesion and energy deployed per unit of tumor volume (< 26.7 J/mm 3 ) were associated with disease progression. In a more recent comparison study, Vogl et al. [74] examined the role of MWA (n = 47 patients) and RFA (n = 41 patients) in the treatment of CRC metastases. These authors reported significantly improved local control rates with MWA over RFA and no significant difference in OS or PFS [74] . However, these studies did not perform histopathologic analysis of ablation zones, via biopsy or resection, to validate technical success.
Cryoablation has also been shown to be safe and effective in the treatment of pulmonary metastases, although survival data are limited [75] . Yamauchi et al. [76] reported a local progression rate of 26% with significantly improved PFS with tumors less than 15 mm in 24 patients with metastatic CRC treated with cryoablation. The 1-and 3-year OS rates were 91% and 59.6% and the 1-and 3-year PFS rates were 90.8% and 59%. McDevitt et al.
[58] found a mean time to local progression of 10 months, with a median OS of 22 months across tumor types treated with cryoablation. A tumor diameter of greater than 3 cm was associated with local progression. Early results from the Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients-Safety and Efficacy (ECLIPSE) trial [77] of 40 patients with 60 lesions are currently being analyzed. The multicenter prospective cohort includes patients with colon (40%), renal (23%), and sarcoma (8%) primaries. The authors report a local control rate at 1 year of 94.2% and a 1-year OS rate of 97.5%. The investigators concluded that these initial results compare favorably with those of other ablation modalities including RFA and MWA [77] . Taken in conjunction with the results of other studies, these results indicate that thermal ablation performs best in tumors less than 3 cm, similar to findings seen with NSCLC.
Comparative Studies
There are limited comparative studies of thermal ablation with other treatment modalities, including surgical resection and stereotactic beam RT. Kim et al. [78] compared the outcomes of patients with stage I NSCLC treated with RFA (n = 8) versus those treated with surgical resection (n = 14). Although the rates of local recurrence were higher in the patients treated with RFA, OS was similar for the two groups [78] . Lee et al.
[60] compared survival in patients with stage I and II NSCLC who were treated with RFA (n = 16) versus those who were treated with surgery (n = 13). Although the patients in the RFA group were significantly older than those in the surgery group, there was no significant difference in OS between the RFA and surgery groups (28.2 and 33.8 months, respectively; p = 0.43) [60] . Zemlyak et al. [79] studied 64 patients with biopsy-proven stage I NSCLC unfit for standard resection. The patients underwent sublobar resection (n = 25), RFA (n = 12), or cryoablation (n = 27). No significant difference in 3-year OS (sublobar resection, 87.1%; RFA, 87.5%; cryoablation, 77%) or in 3-year CSS (sublobar resection, 90.6%; RFA, 97.5%; cryoablation, 90.2%) was seen.
Using the database from the National Cancer Institute's Surveillance, Epidemiology, and End Results program, Kwan et al. [80] examined survival in 1897 patients with early-stage NSCLC who underwent surgical resection or ablation. After propensity score matching was performed, OS and CSS were not significantly different. Alexander et al. [81] compared 56 patients with stage I NSCLC treated with RFA and 28 patients with stage I NSCLC treated with sublobar resection. The 1-, 2-, and 3-year survival rates were 100%, 95%, and 83%, respectively, for the patients who underwent surgery and 91%, 73%, and 55% for those who underwent RFA; there was a significant increase in survival in patients who underwent resection compared with those who underwent RFA [81] .
There are limited data comparing ablation with stereotactic beam RT in the treatment of NSCLC. Ochiai et al. [82] compared outcomes after RFA (n = 48) and stereotactic beam RT (n = 47) in patients with solitary tumors less than 5 cm. The authors reported similar 3-year local control and OS rates between the two modalities: 9.6% and 86.4% for RFA and 7.0% and 79.6% for stereotactic beam RT, with no significant difference between the treatments. However, less than half the patients who underwent stereotactic beam RT had pathologically proven NSCLC [82] . In a pooled analysis of 31 stereotactic beam RT (n = 2767 patients) and 18 RFA (n = 328 patients) studies, Bilal et al. [83] reported that stereotactic beam RT showed lower local progression rates than RFA (3.5-14.5% vs 23.7-43%). OS rates were similar between the two treatments, but 5-year OS rates favored stereotactic beam RT over RFA (47% vs 20.1-27%) [83] .
In the treatment of patients with metastatic disease, RFA compares favorably with surgical resection with reported 5-year OS rates of 27-70% [84] [85] [86] . Large studies detailing the outcomes of stereotactic beam RT in patients with metastatic disease are limited. Fode and Hoyer [87] examined 321 patients with oligometastatic disease treated with stereotactic beam RT. The authors found a median OS of 2.4 years (95% CI, 2.3-2.7 years), with 1-and 5-year OS rates of 80% and 23%. In both primary disease and metastatic disease and unlike surgical resection or stereotactic beam RT, thermal ablation techniques can be repeated with limited changes to pulmonary function [5, 47] . This capability is of particular benefit in the setting of recurrent or residual disease.
Future Directions
Local recurrence remains a limitation of ablative therapy. Several predictors of local recurrence have been reported including tumor size and ablation margin [13, 18, 34] . There has been interest in developing additional biomarkers of disease local recurrence and improved predictors of response. In lung cancer specifically, several oncogenic mutations have been associated with prog-
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nosis [88, 89] . Sofocleous et al. [90] reported the utility of Ki-67 protein as a biomarker for response after RFA in 47 treated tumors, both primary and metastatic. Ki-67-positive tumor cells were an independent marker of local tumor progression and shorter PFS and CSS. Ziv et al. [91] reported that KRAS mutation status of an ablated lesion was a significant predictor of local recurrence that was independent of tumor size or ablation margin in 54 patients with primary adenocarcinoma. Conversely, Wei et al. [92] reported that EGFR-positive status did not adversely affect PFS or OS in 61 patients with stage IIIB or IV NSCLC treated with MWA.
The role of inflammatory cytokines and immune markers for determining prognosis in patients with lung cancer is also being explored. RFA-mediated tumor necrosis can stimulate an immune response [93] . Schneider et al. [93] examined the impact of RFA on the profile of serum inflammatory factors and immune suppressive cells in ablation in 12 patients. In patients with disease recurrence, the investigators found elevated levels of tumor necrosis factor-α, chemokine (CC motif) ligand-2, and chemokine ligand-4 and increased nitric oxide production in circulating myeloid-derived suppressor cells. The authors concluded that these factors may serve as early indicators of incomplete ablation of NSCLC.
Conclusion
Thermal ablation has shown safety and efficacy in the treatment of both primary and secondary lung malignancies in nonsurgical candidates. In NSCLC, after propensity score matching was performed, 2-year OS survival rates match those of surgery and stereotactic beam RT [47, 94] . Ablation also plays a role in metastatic disease, showing safety and efficacy. Across ablation modalities, lesion size is the main determinant of treatment success and survival. Furthermore, local progression remains a limitation for these therapies. Development of new tissue and corresponding surrogate image biomarkers for patient risk stratification and earlier detection of recurrence is needed. Further refinements of ablation technique including the intraprocedural development of tissue confirmation of complete tumor ablation with margins can improve local tumor control and significantly lower recurrence rates. Although ongoing prospective clinical trials comparing the efficacy of thermal ablation, stereotactic beam RT, and surgery are unlikely to mature, they could define the role of these therapies and improve patient selection for each treatment [77, 95] . C B (Fig. 3 continues on next page) Mouli et al. Fig. 3 (continued) -Successful microwave ablation (MWA) of lung metastases from colorectal carcinoma in 37-year-old man with history of ulcerative colitis who had undergone proctocolectomy and formation of J-pouch in 1996. In June 2010, patient was diagnosed with stage I mucinous adenocarcinoma of rectum and received adjuvant chemotherapy (folinic acid, 5-fluorouracil, oxaliplatin) and chemoradiotherapy. In April 2012, patient developed right middle lobe lung metastasis and underwent right middle lobe wedge resection. In February 2013 when patient was no longer receiving chemotherapy, follow-up imaging showed significant progression of disease in left lung with two growing nodules in left lower lobe and left upper lobe. Both lesions underwent MWA with at least 5-mm ablation margins. Tissue from ablation electrodes showed no viable tumor cells [90] . We present imaging of one of two ablated lesions. D, CT scan obtained immediately after ablation shows ablation zone (arrow) of 28 × 30 × 30 mm with minimal ablation margin of more than 10 mm. E, Split-dose 18 F-FDG PET/CT scan obtained after second dose shows no uptake in ablated zone (arrow); maximum standardized uptake value (SUV max ) is 1.0. Histopathologic analysis of tissue from ablation electrodes showed no viable tumor cells [90] . (Split-dose FDG PET/CT is technique for PET/CT-guided ablation that permits both target localization and evaluation of treatment effectiveness. During procedure, standard administered diagnostic FDG activity dose of approximately 12 mCi [444 MBq] is administered in two aliquots: 4-mCi [148-MBq] target dose or imaging dose administered 30-60 minutes before ablation and 8-mCi [296-MBq] treatment efficacy dose administered immediately after ablation. Images are obtained 30 minutes later.) F, FDG PET/CT scan obtained 5 weeks after MWA shows hypermetabolic rim of cavitated ablation zone (arrow). Ablation zone is 2.9 × 4.1 cm with SUV max of 5.5. Followup imaging finding of hypermetabolic rim of cavitated ablation zone was characterized as expected postablation change rather than as residual or recurrent disease. Cavitated ablation zone with hypermetabolic rim can erroneously be interpreted as evidence of local tumor progression. Sequential imaging follow-up with standardized uptake value (SUV) readings is helpful to detect gradual resolution. In cases of focal SUV increase in ablation zone and whenever in doubt, short-interval PET or biopsy is recommended with aim of repeat treatment. G, FDG PET/CT scan obtained 4 months after MWA shows typical collapse and constriction of cavitated ablation zone (arrow), which is 1.6 × 1 cm, and decreased FDG avidity of ablation zone to SUV max of 4.7. H, FDG PET/CT scan obtained 7 months after MWA shows no FDG uptake in ablated area (arrow). I, CT scan obtained 1 year after MWA shows constricted ablation zone (arrow). (Fig. 3 continues on next page) Image-Guided Thermal Ablation of Pulmonary Tumors J Fig. 3 (continued) -Successful microwave ablation (MWA) of lung metastases from colorectal carcinoma in 37-year-old man with history of ulcerative colitis who had undergone proctocolectomy and formation of J-pouch in 1996. In June 2010, patient was diagnosed with stage I mucinous adenocarcinoma of rectum and received adjuvant chemotherapy (folinic acid, 5-fluorouracil, oxaliplatin) and chemoradiotherapy. In April 2012, patient developed right middle lobe lung metastasis and underwent right middle lobe wedge resection. In February 2013 when patient was no longer receiving chemotherapy, follow-up imaging showed significant progression of disease in left lung with two growing nodules in left lower lobe and left upper lobe. Both lesions underwent MWA with at least 5-mm ablation margins. Tissue from ablation electrodes showed no viable tumor cells [90] . We present imaging of one of two ablated lesions. J and K, CT scans obtained 2 years (J) and 4 years (K) after MWA show ablation zone (arrows). L, FDG PET/CT scan obtained 4 years after ablation shows no FDG uptake in ablated area (arrow). After ablation of left lung metastases, patient developed right lung metastasis, which was also treated by MWA. In November 2014, patient developed pleural metastases and pleura-based metastases, which were treated with three regimens of systemic chemotherapy. Patient was alive at last follow-up in 2017.
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